Disclosing this in Hyderabad on Monday, managing director Mahima Datla
said the company is currently evaluating four different formulations
depending on different antigen strengths in the phase I-II combined
studies.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biological-e-to-start-phase-iii-trials-by-january-license-vaccine-by-summer/articleshow/79382405.cms
No comments:
Post a Comment